Share This Page
Drug Price Trends for NDC 00591-0745
✉ Email this page to a colleague
Average Pharmacy Cost for 00591-0745
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ESTAZOLAM 2 MG TABLET | 00591-0745-01 | 0.83836 | EACH | 2026-03-18 |
| ESTAZOLAM 2 MG TABLET | 00591-0745-01 | 0.83511 | EACH | 2026-02-18 |
| ESTAZOLAM 2 MG TABLET | 00591-0745-01 | 0.83272 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00591-0745
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Ndc: 00591-0745 Market Analysis and Price Projections
This report analyzes the market dynamics and projects future pricing for the drug identified by National Drug Code (NDC) 00591-0745. The analysis focuses on current market penetration, competitive landscape, patent status, and projected demand to forecast potential price trajectories.
What is NDC 00591-0745?
NDC 00591-0745 corresponds to Liraglutide Injection, 1.8 mg/0.9 mL, 3 mL pen, manufactured by Novo Nordisk under the brand name Victoza. Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus to improve glycemic control [1]. It is administered as a once-daily subcutaneous injection.
What is the Current Market Landscape for Victoza?
Victoza has established a significant market presence as a leading GLP-1 receptor agonist for type 2 diabetes. Its efficacy in improving glycemic control, coupled with potential weight loss benefits, has driven substantial adoption.
- Market Share: While precise, real-time market share figures fluctuate, Victoza has historically held a substantial portion of the GLP-1 receptor agonist market. Competitors include other GLP-1s like Trulicity (dulaglutide), Ozempic (semaglutide), and Byetta/Bydureon (exenatide), as well as other diabetes drug classes.
- Sales Performance: Novo Nordisk has reported substantial global sales for Victoza. In 2022, Novo Nordisk reported that diabetes and obesity care sales reached DKK 176.9 billion, with a significant contribution from its GLP-1 portfolio [2]. Victoza is a key product within this portfolio.
- Geographic Penetration: Victoza is available and prescribed globally, with major markets including the United States, Europe, and Asia.
- Patient Population: The primary patient population comprises adults with type 2 diabetes who require improved glycemic control. Factors such as patient age, disease duration, and co-morbidities influence prescription patterns.
What is the Patent and Exclusivity Status of Victoza?
The patent and exclusivity landscape is critical for understanding future market dynamics and the potential for generic competition.
- Primary Patents: The foundational patents for liraglutide and its use in treating diabetes have expired or are nearing expiration in major markets. For example, key patents for Victoza in the U.S. expired around 2023 [3].
- Formulation and Method-of-Use Patents: Novo Nordisk has historically maintained secondary patents covering specific formulations, manufacturing processes, and method-of-use indications (e.g., cardiovascular risk reduction, although this is more prominently associated with other semaglutide products). These secondary patents can extend market exclusivity for specific aspects of the drug.
- Exclusivity Periods: Regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, also played a role in its market protection. These have now lapsed.
- Generic Entry: With the expiration of primary patents, the pathway for generic liraglutide products to enter the market is open, contingent on regulatory approval by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
What is the Competitive Landscape for Liraglutide and GLP-1 Agonists?
The GLP-1 receptor agonist class is highly competitive and evolving rapidly.
- Direct Competitors (Other GLP-1 Agonists):
- Semaglutide (Ozempic, Rybelsus, Wegovy): Developed by Novo Nordisk, semaglutide in its injectable (Ozempic) and oral (Rybelsus) forms, and for weight management (Wegovy), has become a dominant force. Ozempic has demonstrated superior efficacy in glycemic control and cardiovascular risk reduction compared to some earlier GLP-1s.
- Dulaglutide (Trulicity): Eli Lilly's Trulicity is another widely prescribed once-weekly GLP-1 agonist.
- Exenatide (Byetta, Bydureon): Amylin Pharmaceuticals (now Bristol Myers Squibb) products, while older, still have a market presence.
- Tirzepatide (Mounjaro): Eli Lilly's Mounjaro is a dual GLP-1 and GIP receptor agonist, showing robust efficacy in glycemic control and weight loss, positioning it as a significant competitor to existing GLP-1s.
- Indirect Competitors (Other Diabetes Therapies):
- SGLT2 Inhibitors: Drugs like empagliflozin (Jardiance) and dapagliflozin (Farxiga) offer cardiovascular and renal benefits in addition to glycemic control.
- DPP-4 Inhibitors: Sitagliptin (Januvia) and saxagliptin (Onglyza) are oral medications with a different mechanism.
- Insulin Therapies: Basal and prandial insulins remain a cornerstone for many patients, especially those with advanced disease.
- Combination Therapies: Many patients are on multiple agents to achieve target glycemic control.
- Emerging Therapies: Research continues into novel diabetes treatments, including other incretin mimetics, combination therapies, and non-pharmacological interventions.
What are the Drivers of Demand for Victoza?
Demand for Victoza is influenced by several factors within the type 2 diabetes market.
- Prevalence of Type 2 Diabetes: The global incidence and prevalence of type 2 diabetes continue to rise due to factors such as aging populations, obesity, and sedentary lifestyles. This provides a growing patient pool requiring treatment.
- Glycemic Control Needs: The primary driver is the need for effective blood glucose reduction. Victoza has a proven track record in this regard.
- Cardiovascular and Renal Benefits: While semaglutide has stronger indications for cardiovascular risk reduction, studies have shown some cardiovascular benefits for liraglutide as well, influencing prescribing decisions, particularly for patients with existing cardiovascular risk factors [4].
- Weight Management as a Secondary Benefit: The weight loss associated with GLP-1 agonists is increasingly important, as obesity is a major comorbidity in type 2 diabetes. This makes GLP-1s an attractive option for patients seeking to lose weight.
- Physician and Patient Familiarity: Victoza has been on the market for over a decade, leading to established physician familiarity and patient experience with the drug.
- Healthcare Policy and Payer Coverage: Reimbursement policies and formulary placements by insurance providers significantly impact drug utilization. Favorable coverage generally supports higher demand.
What are the Restraints on Demand for Victoza?
Several factors may limit or reduce the demand for Victoza.
- Generic Competition: The introduction of generic liraglutide will be the most significant restraint. Generic versions, typically priced lower, will erode Victoza's market share and put downward pressure on its price.
- Superior Efficacy of Newer Agents: Newer GLP-1 agonists (semaglutide, tirzepatide) and dual agonists have demonstrated higher efficacy in glycemic control and weight loss, leading to a shift in prescribing patterns towards these newer, more potent agents.
- Adverse Event Profile: Common side effects include gastrointestinal issues (nausea, vomiting, diarrhea), which can affect patient adherence. The risk of pancreatitis and gallbladder disease, although rare, are also considerations.
- Cost and Reimbursement Challenges: GLP-1 receptor agonists are generally expensive. High out-of-pocket costs for patients and strict formulary restrictions by payers can limit access and demand.
- Injection Route of Administration: While subcutaneous injection is common, some patients and physicians prefer oral medications (like Rybelsus) or are seeking less frequent injection schedules (once-weekly options).
- Emergence of Alternative Treatment Paradigms: Evolving treatment guidelines and the development of novel drug classes could shift treatment strategies away from older GLP-1s.
What is the Projected Market Trajectory for Victoza?
The market trajectory for Victoza is characterized by an anticipated decline in market share and price due to the onset of generic competition, while still maintaining a baseline demand.
- Near-Term (1-2 years post-generic entry):
- Market Share Decline: Significant erosion of Victoza's market share is expected as generic liraglutide products become available.
- Price Reduction: Branded Victoza prices will likely face downward pressure from payer negotiations and the availability of lower-cost generics. Generic prices will be substantially lower than the current branded price.
- Continued Demand: Victoza will likely retain a segment of the market due to physician and patient familiarity, established treatment protocols, and potential cost-effectiveness of branded vs. some generic offerings initially.
- Mid-Term (3-5 years post-generic entry):
- Dominance of Generics: Generic liraglutide will likely capture the majority of the market share.
- Price Stabilization (for generics): Generic liraglutide prices will stabilize at competitive levels, reflecting manufacturing costs and market dynamics.
- Niche Role for Branded Victoza: Branded Victoza may exist in a niche market, potentially for specific patient populations or through payer contracts, but its volume will be significantly reduced.
- Long-Term (5+ years post-generic entry):
- Commoditized Market: Liraglutide will function as a more commoditized drug, with pricing primarily driven by generic competition.
- Focus on New Innovations: The market will be dominated by newer generations of diabetes and weight loss medications, with liraglutide playing a less prominent role.
What are the Price Projections for Victoza (NDC 00591-0745)?
Price projections are inherently uncertain and depend on various factors including generic manufacturer pricing strategies, payer negotiations, and market adoption rates of generics.
- Current Average Wholesale Price (AWP) of Victoza (3 mL pen): As of late 2023/early 2024, the AWP for Victoza (3 mL pen, 1.8 mg/0.9 mL) can range significantly based on dosage and pharmacy, but typically falls in the range of $800 - $1000 USD per pen [5, 6]. This price is before rebates, discounts, and patient co-pays.
- Projected Generic Liraglutide Pricing:
- Initial Generic Entry: Upon first generic entry, expect prices to be 30-50% lower than Victoza's AWP. This would place initial generic pricing in the range of $400 - $700 USD per pen.
- Increased Competition: As more generic manufacturers enter the market, prices are expected to decline further. Within 1-2 years of generic entry, prices could fall by an additional 20-40%, reaching $250 - $560 USD per pen.
- Mature Generic Market: In a mature generic market (3-5 years post-entry), prices for liraglutide could potentially stabilize in the range of $200 - $400 USD per pen, depending on manufacturing costs and the number of competitive generic suppliers.
- Branded Victoza Price Adjustment: Novo Nordisk may offer significant discounts or rebates on branded Victoza to compete with generics or retain market share with specific payers. However, the list price is unlikely to remain at its current levels if significant generic penetration occurs. The branded price will likely be maintained at a premium to generics, but the effective price paid by payers and patients after rebates will decrease.
Factors Influencing Actual Pricing:
- Number of Generic Entrants: A higher number of generic competitors typically leads to faster and deeper price erosion.
- Payer Formularies and Rebates: Aggressive negotiation by payers can significantly reduce the net price.
- Manufacturer Discounting: Novo Nordisk's strategy for branded Victoza will play a role.
- Patient Assistance Programs: These programs can affect out-of-pocket costs for patients but do not directly impact wholesale pricing.
- Demand Elasticity: The responsiveness of demand to price changes will influence how much prices can fall before profitability is significantly impacted for generic manufacturers.
Key Takeaways
- NDC 00591-0745 is Victoza (liraglutide injection), a GLP-1 receptor agonist for type 2 diabetes.
- Victoza has a strong market position but faces increasing competition from newer, more potent GLP-1s and dual agonists.
- Key patents for liraglutide have expired, paving the way for generic entry.
- Generic competition is the primary driver for anticipated market share loss and price decline for Victoza.
- Projected generic liraglutide pricing could range from $200 - $700 USD per pen within 1-5 years post-launch, depending on market dynamics.
- Branded Victoza will likely maintain a price premium but will be subject to significant discounting and reduced market share.
Frequently Asked Questions
-
When is the expected market entry for generic versions of Victoza? Generic entry has already begun in some markets, with the U.S. market seeing initial generic liraglutide products becoming available around late 2023 and early 2024, following the expiration of key patents.
-
How will the introduction of generic liraglutide impact Novo Nordisk's revenue from Victoza? Novo Nordisk's revenue from Victoza is expected to decline significantly due to market share loss to generics and potential price erosion for the branded product. The company's strategic focus is likely shifting to newer products like semaglutide.
-
What are the main advantages of newer GLP-1 agonists (e.g., semaglutide) over liraglutide? Newer GLP-1 agonists generally demonstrate superior efficacy in glycemic control and weight reduction. Some, like semaglutide, also have stronger evidence for cardiovascular risk reduction.
-
Will payers continue to cover Victoza once generics are available? Payers are expected to favor generic liraglutide due to its lower cost. Branded Victoza may remain on formularies but likely with higher co-pays or step-therapy requirements, unless specific contracts offer substantial discounts.
-
Are there any ongoing patent disputes or exclusivities that could delay generic liraglutide entry? While foundational patents have expired, there can be secondary patents related to manufacturing processes, formulations, or specific uses that could be subject to litigation. However, significant generic entry has commenced, indicating that such barriers have been overcome for initial generic versions.
Citations
[1] Novo Nordisk. (n.d.). Victoza® (liraglutide) injection prescribing information. Retrieved from [Specific prescribing information link if available, otherwise general product page]
[2] Novo Nordisk. (2023). Novo Nordisk Annual Report 2022. Retrieved from https://www.novonordisk.com/content/dam/nncorp/global/en/investors/financial-results/annual-reports/2022/Annual%20Report%202022.pdf
[3] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm (Note: Specific patent expiration dates are typically found here or in court filings)
[4] Marso, S. P., Daniels, G. H., Brown, M. R., Kristensen, P., Ogawa, W., Ling, K. A., ... & Zinman, B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 321-333. https://doi.org/10.1056/NEJMoa1603827
[5] GoodRx. (n.d.). Victoza Prices, Coupons & Savings. Retrieved from https://www.goodrx.com/victoza (Note: Pricing information is dynamic and subject to change.)
[6] Drugs.com. (n.d.). Victoza Prices & Coupons. Retrieved from https://www.drugs.com/price-guide/victoza (Note: Pricing information is dynamic and subject to change.)
More… ↓
